Pfizer (PFE) stock in focus as the company with Astellas Pharma (ALPMF) (ALPMY) announce a Phase 3 trial win for their ...

After reporting a 15% sequential decline in Izervay sales for the opening quarter of this year, Astellas has reversed the ...

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

The hot flashes and night sweats that plague breast cancer survivors during years-long hormone-suppressing therapy are eased ...

Astellas Pharma Lands a First-in-Class Drug Approval in Rare Gastrointestinal Cancer The FDA approved Astellas’s Vyloy as a treatment for advanced cases of gastric or gastroesophageal junction ...

Astellas Pharma is far from alone in viewing cancer as a major growth area, but the Japanese drugmaker has specifically identified a type of therapy called targeted protein degradation as one of ...

Astellas Pharma Inc. (ALPMY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in ...

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic ...

Contacts. Contacts for inquiries or additional information: Astellas Pharma Inc. Corporate Advocacy & Relations TEL: +81-3-3244-3201 FAX: +81-3-5201-7473 iota Biosciences, Inc. Richard Berman iota ...

Astellas Pharma Inc. is one of 998 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector ...

Japan's Astellas Pharma said on Monday it agreed to buy U.S. drugmaker Iveric Bio Inc for about $5.9 billion in its biggest acquisition, giving it access to a range of ophthalmology treatments.

Astellas Pharma's next dividend was announced on February 12, 2013 and will have an ex-dividend date of Invalid DateTime. There are no upcoming dividends for Astellas Pharma.The last dividend paid ...